• Testosterone Bounce as a Prognostic Biomarker in Degarelix-T

  2026-07-25

  This study establishes 'testosterone bounce'—a transient rise in serum testosterone above 20 ng/dL during GnRH antagonist therapy—as a promising biomarker for favorable overall and cancer-specific survival in prostate cancer patients treated with degarelix. These findings advance the precision of prognostic monitoring beyond PSA levels and traditional androgen deprivation endpoints.

• Optimizing Epigenetic Modulation: Practical Insights with RG

  2026-07-24

  This article addresses the most common laboratory challenges in epigenetic gene regulation and cell-based assays by providing scenario-driven guidance on the use of RG108 (SKU A1913), a small-molecule DNA methyltransferase inhibitor. Drawing from validated protocols and quantitative data, it equips biomedical researchers and lab technicians with actionable solutions for reproducibility, data interpretation, and reliable vendor selection. Explore how RG108 from APExBIO supports high-fidelity experimental outcomes.

• PCMT1 Drives Ovarian Cancer Metastasis via Anoikis Resistanc

  2026-07-24

  Zhang et al. employed a genome-wide CRISPR/Cas9 knockout screen to identify PCMT1 as a pivotal factor in ovarian cancer metastasis by promoting resistance to anoikis and enhancing tumor cell-ECM interactions. These findings highlight PCMT1 as a promising therapeutic target and advance understanding of mechanisms underlying metastatic progression.

• KPT330 Enhances Cas9 Specificity by Modulating mRNA Nuclear

  2026-07-23

  The reference study reveals that KPT330, an FDA-approved SINE compound, indirectly regulates CRISPR-Cas9 activity by inhibiting Cas9 mRNA nuclear export, thereby improving genome and base editing specificity in human cells. This mechanistic insight advances strategies for reducing off-target effects in genome editing applications.

• Driving CRISPR Precision: Mechanistic Levers in Cas9 mRNA De

  2026-07-23

  This thought-leadership article explores how advanced mRNA engineering—exemplified by EZ Cap™ Cas9 mRNA (m1Ψ)—transforms CRISPR-Cas9 genome editing in mammalian cells. Bridging mechanistic insights, recent peer-reviewed evidence on mRNA nuclear export, and practical strategies, we map a new framework for translational researchers seeking maximum genome editing fidelity, efficiency, and safety. With a critical view of evolving competitive solutions, we outline how next-generation capped Cas9 mRNA tools reshape the landscape, providing translational teams with actionable guidance and a vision for the future.

• SGI-1027 Downregulates DNMT1 to Restore RB1 in Gastric Cance

  2026-07-22

  This study demonstrates that SGI-1027, a DNA methyltransferase inhibitor, suppresses gastric cancer cell growth and metastasis by downregulating DNMT1 and reactivating the RB1 tumor suppressor gene. These findings provide mechanistic insight into epigenetic modulation as a therapeutic strategy for gastric cancer.

• Ceftazidime in Research: Optimizing Third-Generation Cephalo

  2026-07-22

  Ceftazidime stands out as a third-generation cephalosporin for robust modeling of Gram-negative bacterial infection, especially with multidrug-resistant Pseudomonas aeruginosa. This article delivers actionable insights for maximizing experimental reproducibility, from protocol fine-tuning to advanced troubleshooting in resistance-prone assays.

• Ibuprofen’s Mechanistic Impact: From COX Inhibition to Trans

  2026-07-21

  This thought-leadership article explores the dual COX inhibition and anti-proliferative mechanisms of Ibuprofen (2-[4-(2-methylpropyl)phenyl]propanoic acid), highlighting its relevance in colon cancer research and translational workflows. By integrating mechanistic insights, protocol guidance, and the evolving landscape of drug-protein interactions, we deliver strategic recommendations for researchers aiming to bridge preclinical findings to clinical impact. The discussion leverages APExBIO’s high-purity Ibuprofen and recent molecular recognition studies to set a new benchmark for evidence-driven experimental design.

• BRD4 Inhibition Activates AKT-SIRT3 Axis to Protect Against

  2026-07-21

  This study demonstrates that BRD4 inhibition activates the AKT-SIRT3 signaling axis, reducing apoptosis and inflammation in hyperoxia-induced lung injury (HILI). The findings highlight BRD4 as a mechanistically significant target for pulmonary protection, offering new directions for translational epigenetics and lung injury research.

• Substance P: Applied Workflows and Troubleshooting in Pain R

  2026-07-20

  Substance P enables precise dissection of pain, inflammation, and neuroimmune pathways with robust, reproducible protocols. Discover validated workflows, innovative spectral solutions, and expert troubleshooting tips that maximize data fidelity in CNS and immunology research.

• EZ Cap™ Mouse IL-12 mRNA (m1Ψ): Engineering Immunity Beyond

  2026-07-20

  Explore how EZ Cap™ Mouse IL-12 mRNA (m1Ψ) enables precise immunotherapy research by overcoming extrahepatic delivery barriers. This in-depth analysis reveals the molecular innovations and practical protocols that set this cytokine mRNA apart.

• KPT330 Enhances CRISPR-Cas9 Precision via mRNA Nuclear Expor

  2026-07-19

  The reference study demonstrates that the selective inhibitor KPT330 increases the specificity of CRISPR-Cas9 genome and base editing by regulating nuclear export of Cas9 mRNA rather than directly inhibiting the protein. This work provides a new strategy to improve precision in genome editing, with implications for reducing off-target effects in mammalian cell applications.

• Calpeptin: Calpain Inhibitor Workflows for Pulmonary Fibrosi

  2026-07-18

  Calpeptin, a nanomolar-potency calpain inhibitor from APExBIO, uniquely empowers fibrosis and inflammation modeling with highly specific, reproducible inhibition of calpain 1. This article translates bench-to-publication workflows, advanced troubleshooting, and protocol optimization strategies for impactful pulmonary fibrosis and cell death studies.

• Reliable RNA Synthesis for Assays: HyperScribe™ T7 Kit (SKU

  2026-07-17

  This article addresses core laboratory challenges in generating high-quality RNA for cell viability, proliferation, and cytotoxicity assays, focusing on the HyperScribe™ T7 High Yield RNA Synthesis Kit (SKU K1047). Using scenario-driven analysis and literature-backed insights, we demonstrate how this kit ensures consistent results, robust yields, and compatibility with advanced assay needs.

• JNJ-10198409 in Antiangiogenic Research: Deep Mechanistic In

  2026-07-17

  Explore how JNJ-10198409, a potent platelet-derived growth factor receptor inhibitor, enables advanced antiangiogenic and antiproliferative research. This article uniquely integrates signaling insights and protocol precision to push the boundaries of cancer and fibrosis studies.

546 records 10/37 page Previous Next First page 上5页 678910 下5页 Last page